Journals / Turkish Journal of Medical Sciences / 2020 / Cilt: 50 - Sayı: 4

Evaluation of the effects of ß1-selective beta-blockers on bone mineral density and fracture risk in postmenopausal women

Pages
994–998
Publication Date
2020-08-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Based on our results, ß1-selective BB usage was associated with higher BMD at the lumbar region in postmenopausal women.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: ß1-selective beta-blockers BBs are sympatholytic agents, and discerning their effects on bone health would be of great importance.
📊
Key Findings & Data:This study aimed to investigate the influence of ß1-selective BBs on bone mineral density BMD and fracture risk.
💡
Conclusion & Impact:Conclusion: Based on our results, ß1-selective BB usage was associated with higher BMD at the lumbar region in postmenopausal women.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Adrenergic beta-antagonists · postmenopause · bone mineral density

Abstract

Background/aim: ß1-selective beta-blockers BBs are sympatholytic agents, and discerning their effects on bone health would be of great importance. This study aimed to investigate the influence of ß1-selective BBs on bone mineral density BMD and fracture risk. Materials and methods: This study included postmenopausal women who used ß1-selective BBs BB group and control group. Sociodemographic characteristics, BMD and previous fragility fractures were recorded. Additionally, the 10-year probability of a major osteoporotic and hip fracture was calculated using the fracture risk assessment tool FRAX . Results: A total of 60 participants were included in the study. L1-4 and L2-4 BMD values were significantly higher in BB group than control group P = 0.015 and P = 0.025, respectively . Moreover, T-scores of lumbar and femur total were significantly higher in the BB group. Two patients in BB and 6 patients in control group had previous fragility fracture. No statistically significant intergroup difference was noted regarding FRAX. Conclusion: Based on our results, ß1-selective BB usage was associated with higher BMD at the lumbar region in postmenopausal women.

🔖

Cite This Article

KELEŞ, B. Y., VURAL, M., ÖNDER, B., ÖNEŞ, K. (2020). Evaluation of the effects of ß1-selective beta-blockers on bone mineral density and fracture risk in postmenopausal women. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 4, 994–998. https://ajindex.com/articles/113195

References (12)

  1. Black DM, Rosen CJ. Postmenopausal osteoporosis. The New England Journal of Medicine 2016
  2. 374 (3): 254-262. doi: 10.1056/NEJMcp1513724 2. Jackson RD, Mysiw WJ. Insights into the epidemiology of postmenopausal osteoporosis: the Women’s Health Initiative. Seminars in Reproductive Medicine 2014
  3. 32 (6): 454-62. doi: 10.1002/art.38611 3. Diab DL, Watts NB. Postmenopausal osteoporosis. Current Opinion in Endocrinology, Diabetes and Obesity 2013
  4. 20 (6): 501-509. doi: 10.1097/01.med.0000436194.10599.94 4. Qui Y, Yang W, Wang Q,Yan S, Li B et al. Osteoporosis in postmenopausal women in this decade: a bibliometric assessment of current research and future hotspots. Archives of Osteoporosis 2018
  5. 13 (1): 1-8. doi: 10.1007/s11657-018-0534-5 5. Hanley DA, Brown JP, Tenenhouse A, Olszynski WP, Ioannidis G et al. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. Journal of Bone and Mineral Research 2003
  6. 18 (4): 784-790. doi: 10.1359/ jbmr.2003.18.4.784 6. Puth MT, Klaschik M, Schmid M, Weckbecker K, Münster E. Prevalence and comorbidity of osteoporosis- a cross-sectional analysis on 10,660 adults aged 50 years and older in Germany. BMC Musculoskeletal Disorders 2018
  7. 19 (1): 144. 7. Hant FN, Bolster MB. Drugs that may harm bone: mitigating the risk. Cleveland Clinic Journal of Medicine 2016
  8. 83 (4): 281- 288. doi: 10.3949/ccjm.83a.15066 8. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002
  9. 111 (3): 305-317. doi: 0.1016/s0092-8674(02)01049-8 9. Reid IR, Lucas J, Wattie D, Horne A, Bolland M et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism 2005
  10. 90 (9): 5212-5216. doi: 10.1210/jc.2005-0573 10. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000
  11. 100 (2): 197-207. doi: 10.1016/s0092-8674(00)81558-5 11. Solomon DH, Ruppert K, Zhao Z,Lian YJ, Kuo IH et al. Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study. Osteoporosis International 2016
  12. 27 (3): 1181-1189. doi: 10.1007/s00198-015-3332-6 12. Ağaçayak KS, Güven S, Koparal M, Güneş N, Atalay Y et al. Lo